This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Cipla and Pfizer India Partnership
Business marketing agreement

Cipla and Pfizer India Partnership

Analysis based on 6 articles · First reported Dec 19, 2025 · Last updated Dec 20, 2025

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The partnership between Cipla and Pfizer is expected to positively impact both companies. Cipla will benefit from an expanded portfolio and increased market share in India, while Pfizer will gain wider distribution for its key brands, potentially leading to increased sales and patient reach.

Pharmaceuticals
Event Summary

Cipla and Pfizer India have announced an exclusive partnership where Cipla will market, distribute, and sell four of Pfizer's brands in India: Corex Dx, Corex LS, Dolonex, Neksium, and Dalacin C. Pfizer will continue to manufacture and supply these medicines to Cipla. This agreement marks the first collaboration between the two companies in India and aims to leverage Cipla's extensive distribution network to expand the reach of Pfizer's medicines across the country. Both companies expressed optimism about the partnership's potential to meet the healthcare needs of millions of patients in India.

Entities Involved
stock
Cipla
Cipla entered into an exclusive agreement with Pfizer India to market, distribute, and sell four of Pfizer's brands in India, expanding its presence in key therapy areas and leveraging its distribution capabilities.
Importance 100.0 Sentiment 70.0
stock
Pfizer
Pfizer India partnered with Cipla to expand the reach of its medicines across India, while continuing to manufacture and supply the four brands involved in the agreement.
Importance 100.0 Sentiment 60.0
per
Meenakshi Nevatia
Meenakshi Nevatia, Country President of Pfizer India, commented on the partnership's goal to expand the reach of Pfizer's medicines to patients in India.
Importance 30.0 Sentiment 0.0
per
Achin Gupta
Achin Gupta, Global Chief Operating Officer of Cipla, stated that the association with Pfizer aligns with Cipla's focus on building a formidable presence in key therapy areas and enhancing access to high-quality treatments.
Importance 30.0 Sentiment 0.0
stock
Eli Lilly and Company
Importance 0.0 Sentiment 0.0
cnt
India
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.